Marco Falcone1, Francesco Menichetti1, Dario Cattaneo2, Giusy Tiseo1, Sara Baldelli2, Valentina Galfo1, Alessandro Leonildi1,3, Enrico Tagliaferri1, Antonello Di Paolo4, Manjunath P Pai5. 1. Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Pisa, Italy. 2. Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy. 3. Microbiology Unit, Azienda Ospedaliera Universitaria Pisana., Pisa, Italy. 4. Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. 5. Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Avibactam is a β-lactamase inhibitor that is combined with aztreonam against Enterobacterales co-expressing serine- and metallo-β-lactamases (MBL). Optimal dosing of aztreonam with avibactam is not well-defined in critically ill patients and contingent on ceftazidime/avibactam product labelling. OBJECTIVES: To identify a pragmatic dosing strategy for aztreonam with avibactam to maximize the probability of target attainment (PTA). METHODS: We conducted a prospective observational pharmacokinetic study. Five blood samples were collected around the fourth dose of aztreonam or ceftazidime/avibactam and assayed for all three drugs. Population pharmacokinetic (PK) analysis coupled with Monte Carlo simulations were used to create a dosing nomogram for aztreonam and ceftazidime/avibactam based on drug-specific pharmacodynamic (PD) targets. RESULTS: A total of 41 participants (59% male) median age of 75 years (IQR 63-79 years) were enrolled. They were critically ill (46%) with multiple comorbidities and complications including burns (20%). Population PK analysis identified higher volume of distribution and lower clearance (CL) compared with typical value expectations for aztreonam and ceftazidime/avibactam. Estimated glomerular filtration (eGFR) rate using the CKD-EPI equation predicted CL for all three drugs. The need for high doses of aztreonam and ceftazidime/avibactam above those in the existing product labels are not predicted by this analysis with the exception of ceftazidime/avibactam for patients with eGFR of 6-15 mL/min, in whom suboptimal PTA of ≤71% is predicted. CONCLUSIONS: Pragmatic and lower daily-dose options are predicted for aztreonam and ceftazidime/avibactam when the eGFR is <90 mL/min. These options should be tested prospectively.
BACKGROUND: Avibactam is a β-lactamase inhibitor that is combined with aztreonam against Enterobacterales co-expressing serine- and metallo-β-lactamases (MBL). Optimal dosing of aztreonam with avibactam is not well-defined in critically ill patients and contingent on ceftazidime/avibactam product labelling. OBJECTIVES: To identify a pragmatic dosing strategy for aztreonam with avibactam to maximize the probability of target attainment (PTA). METHODS: We conducted a prospective observational pharmacokinetic study. Five blood samples were collected around the fourth dose of aztreonam or ceftazidime/avibactam and assayed for all three drugs. Population pharmacokinetic (PK) analysis coupled with Monte Carlo simulations were used to create a dosing nomogram for aztreonam and ceftazidime/avibactam based on drug-specific pharmacodynamic (PD) targets. RESULTS: A total of 41 participants (59% male) median age of 75 years (IQR 63-79 years) were enrolled. They were critically ill (46%) with multiple comorbidities and complications including burns (20%). Population PK analysis identified higher volume of distribution and lower clearance (CL) compared with typical value expectations for aztreonam and ceftazidime/avibactam. Estimated glomerular filtration (eGFR) rate using the CKD-EPI equation predicted CL for all three drugs. The need for high doses of aztreonam and ceftazidime/avibactam above those in the existing product labels are not predicted by this analysis with the exception of ceftazidime/avibactam for patients with eGFR of 6-15 mL/min, in whom suboptimal PTA of ≤71% is predicted. CONCLUSIONS: Pragmatic and lower daily-dose options are predicted for aztreonam and ceftazidime/avibactam when the eGFR is <90 mL/min. These options should be tested prospectively.
Authors: Michael N Neely; Michael G van Guilder; Walter M Yamada; Alan Schumitzky; Roger W Jelliffe Journal: Ther Drug Monit Date: 2012-08 Impact factor: 3.681
Authors: Mohamad Yasmin; Derrick E Fouts; Michael R Jacobs; Hanan Haydar; Steven H Marshall; Richard White; Roshan D'Souza; Thomas P Lodise; Daniel D Rhoads; Andrea M Hujer; Laura J Rojas; Claudia Hoyen; Federico Perez; Amy Edwards; Robert A Bonomo Journal: Clin Infect Dis Date: 2020-08-14 Impact factor: 9.079
Authors: Andrew S Levey; Josef Coresh; Tom Greene; Lesley A Stevens; Yaping Lucy Zhang; Stephen Hendriksen; John W Kusek; Frederick Van Lente Journal: Ann Intern Med Date: 2006-08-15 Impact factor: 25.391
Authors: Femke de Velde; Brenda C M de Winter; Michael N Neely; Walter M Yamada; Birgit C P Koch; Stephan Harbarth; Elodie von Dach; Teun van Gelder; Angela Huttner; Johan W Mouton Journal: Clin Pharmacokinet Date: 2020-07 Impact factor: 6.447
Authors: Oliver A Cornely; José M Cisneros; Julian Torre-Cisneros; María Jesús Rodríguez-Hernández; Luis Tallón-Aguilar; Esther Calbo; Juan P Horcajada; Christian Queckenberg; Ulrike Zettelmeyer; Dorothee Arenz; Clara M Rosso-Fernández; Silvia Jiménez-Jorge; Guy Turner; Susan Raber; Seamus O'Brien; Alison Luckey Journal: J Antimicrob Chemother Date: 2020-03-01 Impact factor: 5.790